Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
CRISPR/Cas9 loss-of-function screen in a neuronal model of AP-4 deficiency identifies ATG9A trafficking modulators
Marvin Ziegler, Cedric Günter, Julian E. Alecu, Xutong Xue, Hyo M. Kim, Afshin Saffari, Alexandra K. Davies, Mustafa Sahin, Darius Ebrahimi-Fakhari
Marvin Ziegler, Cedric Günter, Julian E. Alecu, Xutong Xue, Hyo M. Kim, Afshin Saffari, Alexandra K. Davies, Mustafa Sahin, Darius Ebrahimi-Fakhari
View: Text | PDF
Research Article Cell biology Genetics Neuroscience

CRISPR/Cas9 loss-of-function screen in a neuronal model of AP-4 deficiency identifies ATG9A trafficking modulators

  • Text
  • PDF
Abstract

Biallelic loss-of-function variants in adaptor protein complex 4 (AP-4) disrupt trafficking of transmembrane proteins at the trans-Golgi network, including autophagy-related protein 9A (ATG9A), leading to childhood-onset hereditary spastic paraplegia (AP-4-HSP). AP-4-HSP is characterized by features of both a neurodevelopmental and a degenerative neurological disease. To investigate the molecular mechanisms underlying AP-4-HSP and identify potential therapeutic targets, we conducted an arrayed CRISPR/Cas9 loss-of-function screen of 8,478 genes, targeting the “druggable genome,” in a human neuronal model of AP-4 deficiency. Through this phenotypic screen and subsequent experiments, key modulators of ATG9A trafficking were identified, and complementary pathway analyses provided insights into the regulatory landscape of ATG9A transport. Knockdown of ANPEP and NPM1 enhanced ATG9A availability outside the trans-Golgi network, suggesting that they regulate ATG9A localization. These findings deepen our understanding of ATG9A trafficking in the context of AP-4 deficiency and offer a framework for the development of targeted interventions for AP-4-HSP.

Authors

Marvin Ziegler, Cedric Günter, Julian E. Alecu, Xutong Xue, Hyo M. Kim, Afshin Saffari, Alexandra K. Davies, Mustafa Sahin, Darius Ebrahimi-Fakhari

×

Figure 3

Primary screen identifies modulators of ATG9A trafficking.

Options: View larger image (or click on image) Download as PowerPoint
Primary screen identifies modulators of ATG9A trafficking.
(A) Distribut...
(A) Distribution of robust z scores from the primary screen. Genes are categorized as toxic (robust z score for cell count < –3 in at least 2 replicates), not toxic, or hits (not toxic and robust z score for ATG9A ratio < –3 in all replicates). A total of 92 genes were identified as hits, while 1,041 genes were classified as toxic. (B) Ranked distribution of robust z scores for all screened genes. Genes with a mean robust z score less than –3 across all replicates are highlighted. While only 92 genes met the stringent cutoff criteria of robust z scores less than –3 in all replicates and were classified as hits, 764 genes exhibited a mean robust z score less than –3 across all replicates, indicating a strong but less reproducible impact on ATG9A trafficking.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts